Corcept (CORT) Stock Jumps 109.1%: Will It Continue to Soar?

This drug developer is expected to post quarterly earnings of $0.17 per share in its upcoming report, which represents a year-over-year change of -32$177.97 million, up 21.2% from the year-ago quarter. Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements. Corcept Therapeutics (CORT) shares ral ...